8 May, 2025HAYA Therapeutics raises $65 million in Series A funding to deliver precision RNA-guided medicines for chronic and age-related diseases
30 April, 2025NodThera’s oral NLRP3 inhibitor NT-0796 enhances and sustains weight loss in combination with GLP-1
28 April, 2025Mainstay Medical announces exclusive coverage of ReActiv8® by Anthem Blue Cross/Blue Shield
28 April, 2025Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
24 April, 2025CorWave announces successful completion of 6-month chronic in vivo study, paving the way for clinical trial initiation